Mayo Clinic-ko ikertzaileekin lankidetzan egindako argitalpenak (22)

2024

  1. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

2023

  1. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials

    JAMA Oncology, Vol. 9, Núm. 4, pp. 490-499

2022

  1. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  2. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review

    Breast Cancer Research and Treatment, Vol. 194, Núm. 1, pp. 1-11

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Practice Choices in Targeted Intrathecal Drug Delivery: An Online Survey Conducted by the Polyanalgesic Consensus Committee

    Neuromodulation

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. A Systematic Literature Review of Peripheral Nerve Stimulation Therapies for the Treatment of Pain

    Pain Medicine (United States), Vol. 21, Núm. 8, pp. 1590-1603

  2. How to Restart the Interventional Activity in the COVID-19 Era: The Experience of a Private Pain Unit in Spain

    Pain Practice, Vol. 20, Núm. 8, pp. 820-828

  3. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

    British Journal of Cancer

2019

  1. Breast cancer

    Nature Reviews Disease Primers, Vol. 5, Núm. 1

2018

  1. Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol

    Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357

2017

  1. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

    Breast Cancer Research and Treatment, Vol. 163, Núm. 3, pp. 535-544

  2. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7)

    Breast Cancer Research and Treatment

  3. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

    European Journal of Cancer, Vol. 76, pp. 205-215

  4. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

    Breast Cancer Research and Treatment, Vol. 165, Núm. 2, pp. 329-341

  5. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks

    Neuromodulation, Vol. 20, Núm. 2, pp. 155-176

2016

  1. Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

    Cancer and Metastasis Reviews, Vol. 35, Núm. 2, pp. 323-332

  2. Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

    SpringerPlus, Vol. 5, Núm. 1

2015

  1. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 15, pp. 1556-1568